Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10381161" target="_blank" >RIV/00216208:11140/18:10381161 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/18:10381161

Výsledek na webu

<a href="https://doi.org/10.1111/all.13433" target="_blank" >https://doi.org/10.1111/all.13433</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/all.13433" target="_blank" >10.1111/all.13433</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial

Popis výsledku v původním jazyce

Background: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. Methods: In a randomized, double-blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. Results: The mean reduction in CSMS in the LPP vs placebo group was MINUS SIGN 15.5% (P =.041) during the peak period and MINUS SIGN 17.9% (P =.029) over the entire pollen season. LPP-treated group had a reduced reactivity to CPT (P &lt;.001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P =.005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed LESS-THAN OR EQUAL TO30 minutes in 10.5% of LPP-treated patients, whereas 3 patients with a medical history of asthma (&lt;1%) experienced a serious ESR that resolved with rescue medication. Conclusion: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well-tolerated. (C) 2018 The Authors. Allergy Published by John Wiley &amp; Sons Ltd.

Název v anglickém jazyce

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial

Popis výsledku anglicky

Background: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. Methods: In a randomized, double-blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. Results: The mean reduction in CSMS in the LPP vs placebo group was MINUS SIGN 15.5% (P =.041) during the peak period and MINUS SIGN 17.9% (P =.029) over the entire pollen season. LPP-treated group had a reduced reactivity to CPT (P &lt;.001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P =.005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed LESS-THAN OR EQUAL TO30 minutes in 10.5% of LPP-treated patients, whereas 3 patients with a medical history of asthma (&lt;1%) experienced a serious ESR that resolved with rescue medication. Conclusion: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well-tolerated. (C) 2018 The Authors. Allergy Published by John Wiley &amp; Sons Ltd.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30225 - Allergy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Allergy

ISSN

0105-4538

e-ISSN

—

Svazek periodika

73

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

1842-1850

Kód UT WoS článku

000443222400009

EID výsledku v databázi Scopus

2-s2.0-85052753982